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RESUMO 
 
 
Introdução e objetivos 
O transplante hepático sequencial (THS) consiste na utilização de fígados excisados de 
doentes com amiloidose por transtirretina (ATTR) hereditária como enxertos para outros 
doentes com patologias hepáticas graves e com prognóstico reservado. 
O nosso objetivo era investigar o desenvolvimento de manifestações cardíacas de 
amiloidose por transtirretina iatrogénica (ATTRi) em doentes com THS. 
Métodos 
Analisámos retrospetivamente os dados clínicos e exames de 72 doentes consecutivos 
submetidos a THS entre 2007 e 2010 no nosso centro, que receberam fígados com 
mutação V30M.  
Resultados 
A nossa amostra tinha 79% de homens,  idade mediana aquando do transplante de 56 
anos, com mediana de tempo de seguimento de 80 meses (IQR 21-101). 
Após uma mediana de 17 meses, 44% morreram. Manifestações de ATTRi ocorreram em 
29%, em média 6 anos após THS; em 76% dos doentes nos quais foi realizada biópsia foi 
detetada amilóide. 
Alterações significativas da condução cardíaca foram raras (apenas 1 doente); contudo, 
verificou-se uma tendência aumentar o intervalo PR e ocorreu fibrilhação/flutter auricular 
em 8%. 
Sinais de envolvimento miocárdico foram relativamente mais frequentes, nomeadamente 
aumento da espessura miocárdica com fração de ejeção preservada. Desenvolveu-se 
presumível miocardiopatia infiltrativa em 9 casos (12,5%), após uma mediana de 68 meses 
(IQR 26-96). 
Conclusões 
Os doentes que fizeram THS tiveram mortalidade considerável, ocorrendo ATTRi mais 
frequentemente e precocemente do que esperado. Um padrão de miocardiopatia infiltrativa 
foi mais comum e alterações da condução mais raras do que seria previsível a partir de 
dados de ATTR V30M hereditária. 
 
 
 
Palavras-chave: Transplante hepático sequencial; amiloidose; condução elétrica 
cardíaca; miocardiopatia infiltrativa; insuficiência cardíaca. 
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ABSTRACT   
 
 
Introduction and purpose 
Domino liver transplantation (DLT) is a procedure that uses the livers excised from patients 
with hereditary transthyretin-related amyloidosis during liver transplantation as grafts to 
other patients with severe hepatic pathologies and a reserved prognosis.  
Our aim was to investigate the development of cardiac manifestations consistent with 
iatrogenic transthyretin amyloidosis (iATTR) in recipients of DLT.  
Methods 
We retrospectively analyzed the medical records and exams of 72 consecutive patients 
submitted to DLT between 2007 and 2010 in our centre, who received livers with V30M 
mutation. 
Results 
Our sample had 79% male patients, median age at transplantation of 56 years and median 
follow-up time of 80 months (IQR 21-101).  
After a median of 17 months, 44% of the patients died. Manifestations of iATTR occurred 
in 29%, on average 6 years after DLT, and amyloid was seen in 76% of those who 
underwent a biopsy.  
Significant conduction changes were rarely seen (present in 1 patient); however there was 
a trend towards an increase in PR interval and atrial fibrillation/ flutter was reported in 8%.  
Signs of myocardial involvement were relatively more common, namely increased wall 
thickness with preserved ejection fraction. Presumed infiltrative cardiomyopathy was found 
in 9 cases (12.5%), after a median of 68 months (IQR 26-96) after DLT. 
Conclusions 
Patients that underwent DLT had a considerable mortality rate and iATTR occurred more 
frequently and earlier than expected. A pattern of infiltrative cardiomyopathy was relatively 
more common and conduction disorders rarer than one would extrapolate from hereditary 
ATTR V30M data. 
 
 
 
 
 
Key-words: Domino liver transplantation; amyloidosis; cardiac electric conduction; 
infiltrative cardiomyopathy; heart failure 
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INTRODUCTION 
 
 
Hereditary transthyretin related amyloidosis (ATTR) is an autosomal dominant disease 
caused by extracellular deposition of mutated transthyretin, forming amyloid fibrils due to 
destabilization of the tetramer.[1-5] Although more than 100 different mutations in 
transthyretin (TTR) have been described, the most common is V30M.[2, 5, 6] There is an 
endemic area of early onset disease in the north of Portugal, with ATTR V30M mutation 
(V50M in the new nomenclature),[7] characterized by slowly progressive sensory-motor 
peripheral and autonomic neuropathy [1-4, 6, 8] and designated as Familial Amyloid 
Polyneuropathy (FAP).  Centro Hospitalar do Porto is a reference centre for the treatment 
of this disease and even though the hallmark manifestation of TTR-FAP is neurological, it 
may also have cardiovascular, gastrointestinal, ophthalmologic, renal and urological 
manifestations.[2-4, 8]  
Transthyretin is mainly produced by the liver [1, 3, 4, 9-11] – in spite of being also formed in the 
retinal pigment epithelium and in the choroid plexus in small quantity [12, 13] -  and liver 
transplantation (LT) emerged as the first effective treatment of the disease, which may 
detain its progression.[2, 3, 9-11]  On the other hand, orthotopic liver transplantation is also 
frequently used in the treatment of severe liver diseases. [10] 
Since one of the major limitations of LT is the shortage of organs for transplantation, the 
livers excised from TTR-FAP patients during LT began to be used for transplantation of 
other patients with severe hepatic pathologies and a reserved prognosis (who would 
therefore not be candidates for LT). Considering that the liver of a patient with TTR-FAP is 
anatomically and functionally normal, except for producing mutated transthyretin, [14] it was 
presumed that a proportion of the recipients would never present the disease or that it would 
take decades before the first manifestations of systemic amyloidosis – since patients usually 
have symptoms of the disease from the third decade of life onwards. This process is called 
sequential or domino liver transplantation (DLT) [3, 4, 10, 15]and was first performed in 1995 in 
Portugal. [15-17]  
This surgery has increased the supply of hepatic grafts that could be used in transplantation 
and enabled the treatment of older individuals or patients with a worse prognosis who would 
not be transplanted. [18] In addition, it has the advantage that donors are generally young 
and the time of ischemia is shorter. Thus, in some centres the criteria for DLT have been 
broadened.[2, 3, 8, 10, 19] 
However, few studies have evaluated the long-term results of DLT and some published 
cases have shown that the manifestations of acquired or iatrogenic transthyretin-related 
amyloidosis (iATTR) are not always as late as anticipated.[2, 4, 9, 14, 20, 21] 
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Cardiac amyloidosis may or may not be related with systemic impairment[22, 23]. In patients 
with a non-cardiac biopsy presenting amyloid deposition, cardiac involvement is usually 
defined as either a positive heart biopsy, unexplained low voltage on the ECG and/or 
increased left ventricular wall thickness (an interventricular septal thickness >12 mm, in the 
absence of hypertension or other potential causes of left ventricular hypertrophy). [23, 24] 
The main manifestations of cardiovascular disease in these cases are the conduction 
disorders, such as sinus node disease, atrioventricular (AV) blocks  and intraventricular 
conduction delays or bundle branch blocks, which may require permanent pacemaker.[25] 
However, myocardial infiltration with amyloid is also frequently present. Typical 
abnormalities involve increased right and left ventricular wall thickness with normal cavity 
size, diastolic dysfunction, as well as the progressive thickening of the atrial septum, 
increased myocardial echogenicity, valve thickening and pericardial effusion.[26-28] Left 
ventricular (LV) systolic impairment is rare and a typical pattern of relative apical sparing of 
longitudinal strain has been described. [29] There were also found common some 
electrocardiographic features as low voltage, pseudo-infarction pattern, poor R wave 
progression in the precordial leads and arrhythmias, including atrial fibrillation and flutter.[22, 
23, 26, 30] 
The development of congestive cardiac failure is possible, and death can ensue within 6 
months.[23] 
 
Our aim is to describe the development of cardiac manifestations consistent with iatrogenic 
TTR amyloidosis (iATTR) in patients that underwent DLT and received the liver of a patient 
with TTR-FAP. We will evaluate the occurrence of changes in the electric conduction 
system of the heart and myocardium involvement, namely development of heart failure and 
features of an infiltrative cardiomyopathy. We intend to analyze the occurrence of iATTR, 
the timing of these manifestations and the prognosis of these patients.  
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METHODS  
 
 
This is a retrospective observational study that includes 72 patients submitted to DLT at 
Centro Hospitalar do Porto (Porto, Portugal), between January 2007 and December 2010. 
They received livers from patients with hereditary ATTR caused by V30M mutation.  
We collected demographic information, clinical characteristics, laboratorial and imaging 
data, through consultation of the clinical information and exams.  
This study was approved by our centre’s ethical committee (N/REF.ª 2018.023(022-
DEFI/022-CES). 
 
Statistical analyses  
Continuous data are described as mean ± standard deviation or median (25-75 interquartile 
range) for non-gaussian distributions. Categorical data are presented as absolute 
frequencies (n) and percentages.  
Continuous variables were compared using t test or Mann-Whitney U test, as appropriate, 
and categorical variables using Fisher’s exact test.  
The intra-individual comparison of parameters during follow-up was done using t paired-
sample test or Wilcoxon signed-rank test, or McNemar test for categorical variables.  
We used SPSS® software, version 23, considering p<0.05 for statistical significance. 
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RESULTS  
 
 
We included 72 patients submitted to DLT at our centre; 79% (n=57) were male, with a 
median age at transplantation of 56 years (IQR 50-60; range 54-72) – Table 1. 
The most common reasons for undergoing liver transplantation were: alcoholic cirrhosis 
(44%), hepatocellular carcinoma (31%) and chronic liver disease nonalcoholic and nonviral 
(10%).  
During a median follow-up time of 80 months (IQR 21-101), 44% (n=32) died, after a median 
of 17 months (range 0 to 106 months).  
A fatal complication (directly or not) related to the transplant occurred in 32% of the patients, 
whereas 29% had a nonfatal complication.  
As per the medical records, 8 patients were considered for re-transplantation: 3 were 
retransplanted (1 because of amyloidosis and 2 because of graft dysfunction) and 5 were 
in the waiting list.  
Iatrogenic ATTR was diagnosed in 21 patients (29%), 68 ± 25 months after DLT (median 
71, range 20 to 110 months). 
Of the 43 patients that underwent a biopsy, it was positive for amyloid in 33 cases (46% of 
the total), on average 56 ± 13 months after DLT (range 30 to 86 months). Most biopsies 
were of the salivary glands, that are used routinely at our centre. 
Neurological symptoms of iATTR were reported in 20 patients, on average 68 ± 27 months 
after DLT. In 10 patients, gastrointestinal symptoms were present, urologic symptoms in 3, 
ophthalmologic in 2 and renal also in 2 patients. In most patients (n=20), the first symptoms 
of iATTR were neurological.  
In terms of potential confounders, 33 patients had diabetes or another possible cause for 
peripheral neuropathy.[14, 17, 21, 31] 
 
- Electric conduction changes 
Significant conduction changes (second degree Mobitz II or third degree AV block; 
symptomatic sinus node disease or another general indication for pacemaker implantation) 
[30, 32-35] were reported in just one patient (that died before pacemaker implantation). 
A permanent pacemaker was implanted in 2 patients, in both cases “prophylactically” before 
re-transplant. 
Bradycardia, defined as heart rate < 50 bpm, was registered in 7 patients. 
Atrial fibrillation or flutter occurred in 6 patients (8%), no other supraventricular or ventricular 
arrhythmias were reported (Table 2). 
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Between baseline and 6 years of follow-up, the PR interval significantly increased and the 
voltage in the precordial leads (measured as Sokolow index) decreased – Table 2. 
Pathological Q waves, repolarization changes and poor R wave progression in the 
precordial leads were frequently seen (Table 2).  
 
- Myocardial involvement 
Myocardial involvement of iATTR (Table 3) was assumed in 9 patients (12.5%), on average 
65 ± 35 months after DLT (median 68; IQR 26-96): 3 had a phenotype of cardiac 
amyloidosis and symptoms of heart failure, 4 had heart failure symptoms without a milder 
phenotype, 2 had phenotypic changes without evident heart failure symptoms. An additional 
patient had phenotypic changes suggestive of heart failure before DLT.  
Of the 55 patients that had records of an echocardiogram at baseline, 22 had increased 
wall thickness (12 mm). Of the 26 that repeated echo, 17 (65%) had increased wall 
thickness; 7 of those had normal wall thickness at baseline. There was a non-significant 
trend towards an increase in wall thickness (p= 0.077). 
Only 1 patient had compromised LV systolic function, already present pre-transplant, and 
died with acute transplant complications. 
ProBNP levels did not significantly change during follow-up (Table 4). 
In terms of potential confounders for interpreting LV wall thickness and proBNP levels, it is 
important to consider that during follow-up 28 patients had hypertension and 28 had chronic 
kidney disease. 
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DISCUSSION & CONCLUSIONS 
 
 
A significant proportion of the DLT recipients developed manifestations of iATTR:  29% 
were formally diagnosed with iATTR, on average 6 years after DLT. Moreover, in 76% of 
those that had a biopsy, it was positive for amyloid, which is in line with other studies that 
claim that deposition of amyloid, for example in the GI tract and skin as well as in the salivary 
glands, can precede clinical symptoms. [36-38] So even if the symptoms were not clear-cut, 
we can consider that tissue involvement was present in all those patients, on average 5 
years after DLT. 
In what concerns cardiovascular involvement, disturbances of the electrical conduction 
system were rare, but could possibly be detected with a longer follow-up and systematic 
examinations. Significant conduction changes were reported in just one patient; bradycardia 
occurred in 10% and 2 patients implanted a “prophylactic” pacemaker. Atrial fibrillation or 
flutter was registered in 8% of our sample. 
Signs suggestive of myocardial involvement were not uncommon after LT, namely 
increased wall thickness during follow-up and probable infiltrative cardiomyopathy was seen 
in 9 cases (12.5%). The definitive diagnosis of cardiac amyloidosis is often difficult to make 
in these patients, especially since the hallmark of increased wall thickness and diastolic 
dysfunction can also be related to other factors such as aging and hypertension. [39] In this 
regard, cardiac magnetic resonance, 99mTc-DPD (99m technetium labelled 3,3-
diphosphono-1,2-propanodicarboxylic acid) scintigraphy, 123-iodine 
metaiodobenzylguanidine (MIBG) imaging, advanced echocardiographic analysis using 
strain and endomyocardial biopsy can be particularly useful, even though they were not 
routinely used in our sample. 
As we could understand from the data, after evident clinical symptoms and amyloid 
deposition was proved, some patients underwent retransplantation. The aim of this surgery 
is based in the multiple evidence that LT can stop the progression of the hereditary disease. 
Yet, several studies have shown that conduction changes and cardiomyopathy caused by 
amyloid deposition are not reversible by LT and continue to develop after liver 
transplantation in patients with hereditary amyloidosis, and heart transplantation is rarely a 
possibility. [23, 26, 39, 40] 
The concept that iATTR would manifest only around 25-30 years after DLT was proven 
wrong, possibly because of epigenetic and aging factors that are involved in 
amyloidogenesis. In fact, some articles demonstrate that the advanced age of the recipient 
can be a cause of early de novo amyloid deposition in the tissue. It was also observed more 
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severe deposition in these patients. However, the possibility that part of this amyloid 
deposition is due to wild-type TTR, which is common in elderly people, is not excluded.[8, 37] 
Nevertheless, DLT can be a valid option for patients that are not candidates for LT or with 
a very poor short-term prognosis. [8, 21, 37, 41] When DLT was first described, only one patient 
had survived more than 5 years [16]; in our sample, 46 patients (64%) survived more than 5 
years.  
The risks and benefits of DLT and the expected course of iATTR should be thoroughly 
discussed with the patients and we recommend that they are followed by a multidisciplinary 
team that would perform at least a neurologic and cardiologic assessment, at baseline and 
every year after transplantation (since iATTR can manifest itself 20 months after DLT).  
Our study has several limitations, essentially due to its retrospective and observational 
design; the small sample size and missing data did not allow us to properly analyse several 
parameters, such as echocardiographic data, troponin or proBNP levels. Data from Holter 
monitoring was also rare. 
This study highlights the importance of a systematic follow-up of these patients, what can 
help us to better understand and intervene on iATTR, and possibly will also enlighten our 
understanding of hereditary ATTR amyloidosis. 
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TABLES 
 
Table 1 - Study sample characterization 
 
Age at transplantation; median (IQR) 56 (50-60) 
Male gender; n (%) 57 (79%) 
Main reason for LT; n (%) 
      Alcoholic cirrhosis             
      Hepatocellular carcinoma 
      Chronic liver disease non alcoholic non viral 
      Primary biliary cholangitis 
      Viral hepatitis/ cirrhosis 
      Caroli disease/ repeated colangitis 
 
32 (44%) 
22 (31%) 
7 (10%) 
5 (7%) 
4 (6%) 
2 (3%) 
Iatrogenic ATTR amyloidosis1, n (%) 
      Neurological symptoms, n  
      Cardiovascular symptoms, n 
      Gastrointestinal symptoms, n 
      Urologic symptoms, n 
      Ophalmologic symptoms/ signs, n 
      Renal manifestations, n 
21 (29%) 
20 
8 
10 
3 
2 
2 
Diabetes mellitus or other potential cause for peripheral 
neuropathy; n (%) 
33 (46%) 
Hypertension; n (%) 28 (39%) 
Chronic kidney disease; n (%) 28 (39%) 
Atrial fibrillation /flutter; n (%) 6 (8%) 
Other supraventricular arrhythmias/ tachycardia 0 
Ventricular tachycardia 0 
Significant conduction changes2; n (%) 1 (1%) 
 14 
 
Pacemaker implantation, n (%) 2 (3%) 
Probable heart failure3; n (%) 10 (14%) 
Death; n (%) 32 (44%) 
 
1Symptoms could be cumulative. 
2 Second degree Mobitz II or third degree atrioventricular block; symptomatic sinus node 
disease or another general indication for pacemaker implantation. 
3 Defined as signs or symptoms compatible with heart failure. 
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Table 2 - Electrocardiographic changes during follow-up 
 
 
Baseline 
(n= 47) 
2 years 
(n=11) 
4 years 
(n= 35) 
6 
years 
(n=40) 
8 years 
(n=23) 
10 
years 
(n=4) 
p 
PR interval (ms); 
mean ± SD 
61 ± 29 
158 ± 
21 
173 ± 
28 
172 ± 
29 
181 ± 
42 
154 ± 
23 
0.003 
QRS interval 
(ms); mean ± SD 
97 ± 15 99 ± 16 96 ± 15 97 ± 16 97 ± 20 95 ± 7 0.330 
Sokolow index 
(mV); mean ± SD 
23 ± 6 28 ± 6 20 ± 6 19 ± 7 25 ± 15 20 ± 4 0.019 
Maximum 
voltage in the 
limb leads (mV); 
mean ± SD 
9 ± 3 11 ± 3 10 ± 3 10 ± 4 11 ± 5 9 ± 4 0.656 
Mobitz I second 
degree AV; n (%) 
0 0 0 0 0 0 - 
High degree AV 
block (Mobitz II, 
2:1 or third 
degree AV 
block); n (%) 
0 0 0 0 0 0 
- 
 
LBBB; n (%) 1 (2%) 0 0 0 0 0 1.000 
Pathological Q 
waves; n (%) 
10 (21%) 1 (9%) 8 (23%) 
12 
(30%) 
6 (26%) 1 (25%) 0.375 
Repolarization 
changes; n (%) 
20 (43%) 5 (45%) 
10 
(29%) 
18 
(45%) 
8 (35%) 0 1.000 
Poor R wave 
progression in 
the precordial 
leads; n (%) 
10 (21%) 1 (9%) 5 (14%) 7 (18%) 6 (23%) 0 1.000 
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The last column compares the baseline means or proportions to those at 6 years (given that 
those were the time points with more observations), using paired-sample t test or related-
samples McNemar test, respectively.  
Legend: AV – atrioventricular; LBBB- left bundle branch block.  
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Table 3 - Echocardiographic evaluation 
 
 
 Echocardiographic parameters Baseline TTE 
(n= 64) 
Repeated TTE 
(n= 26) 
Maximum left ventricular wall thickness (mm); 
mean ± SD 
11 ± 1 12 ± 2 
Increased left ventricular wall thickness; n (%) 
 
 
22 (34%), 
3 moderate 
and 19 mild 
17 (65%), 
4 moderate and 
13 mild 
Increased right ventricular wall thickness; n (%) 0 0 
Left ventricular telediastolic diameter (mm); mean 
± SD 
48 ± 4 42 ± 10 
Left ventricular dilatation; n (%) 1 (1,6%) 0 
Right ventricular dilatation; n (%) 1 (1,6%) 1 (3,8%) 
Left ventricular systolic function; n (%)   
- Normal  63 (98,4%) 26 (100%) 
- Mildly compromised 1 (1,6%) 0 
- Moderately compromised 0 0 
- Severely compromised 0 0 
Compromised right ventricular systolic function; n 
(%) 
0 0 
Significant valvular disease; n (%) 1 (1,6%) 1 (3,8%) 
Left atrial dilatation; n (%) 31 (48%) 16 (62%) 
Granular appearance of the left ventricular walls; n 
(%) 
0 0 
Pulmonary artery systolic pressure (mmHg); mean 
± SD 
32 ± 8 25 ± 6 
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Dilated inferior vena cava and/or with decreased 
inspiratory collapse; n (%) 
2 (3%) 1 (3,8%) 
Pericardial effusion; n (%) 1 (1,6%) 0 
 
Continuous variables are presented as mean ± standard deviation (SD).  
The interval between the first and second echocardiogram was on average of 61 ± 32 
months.  
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Table 4 - ProBNP values during follow-up 
 
 
Baseline 2 years 4 years 6 years 8 years 10 years 
263 
(102; 789) 
127 
(65-275) 
139 
(91; 365) 
130 
(67; 487) 
335 
(139; 802) 
125 
(76; 2645) 
 
Values presented as median (quartiles 25; 75), in ng/mL. 
 
